Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
about
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacyVasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activationRole of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized ratsMolecular cloning, pharmacological properties and tissue distribution of the porcine 5-HT(1B) receptorStudy of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized ratPharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteriesEvaluation of the changes in the nasal cavity during the migraine attack.Neurogenic inflammation in the context of migraine.The trigeminovascular system in bacterial meningitis.Sport and exercise headache: Part 2. Diagnosis and classification.The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.Modelling headache and migraine and its pharmacological manipulationNeuroleptics in headache.Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva.Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms.Review of zolmitriptan and its clinical applications in migraine.5-HT(1D) receptor immunoreactivity in the sphenopalatine ganglion: implications for the efficacy of triptans in the treatment of autonomic signs associated with cluster headache.Migraine: preventive treatment.No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery.Molecular cloning, sequence analysis and pharmacological properties of the porcine 5-HT(1D) receptorEP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteriesSelective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development.The place of corticosteroids in migraine attack management: A 65-year systematic review with pooled analysis and critical appraisal.Emerging drugs in migraine treatment.Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulationNaratriptan: a review.Effects of sumatriptan on the cerebral intraparenchymal microcirculation in the cat.Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619Evidence-based understanding of medication-overuse headache: clinical implications.Migraine and adiponectin: is there a connection?Triptans in pregnancy.Review of frovatriptan in the treatment of migraineIntravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat.Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies.Preventive treatment in migraine and the new US guidelinesA pharmacogenomic evaluation of migraine therapy.Pro-inflammatory effects of hydrogen sulphide on substance P in caerulein-induced acute pancreatitis.Medullary pain facilitating neurons mediate allodynia in headache-related painMigraine in the triptan era: progresses achieved, lessons learned and future developments.Migraine: an overview.
P2860
Q24321991-5C9777AA-61B7-4580-A014-ECB6789DFB63Q24564969-CDC4379A-FB78-490E-AADA-395A48FF6192Q28343904-D8D8326A-5DEC-4784-A192-9F227F91A136Q28343925-42E722F5-D7FA-4AB3-B24F-1182F105257DQ28565111-8E17C8B1-9B13-4FD6-9497-00277A17CEEFQ33867649-EFE632DF-2601-4B64-98F9-9FE2A49695E8Q34167587-6F85D52D-DDAE-4CAD-A0A3-BB2864CCB5A3Q34218309-60C39F9C-7EA1-470E-898D-0014206B3FA0Q34218327-AC9CA015-6E2A-4834-AF8C-307EA917069AQ34264063-21DBE00B-FF19-42C0-BD30-537103A91476Q34373285-B802C609-F47A-4EB0-838F-F2C21F4F11FBQ34407137-98EFC636-55EF-4A9F-B973-7A90ACBD3A09Q34412065-CF78C8AC-A0F9-429B-B97D-FCFA74A81C40Q34662470-8A3DC650-4FBE-4BD7-AFB0-B790D60C9002Q34662700-4AF39003-C69D-4C97-A092-F18BEE126B0EQ34706949-AE98ED9C-F4F3-46B1-AA52-928B2415B2C1Q34775138-99279BEF-105B-468F-ABDA-3D8427A4785FQ34852689-222BD3E1-4473-4373-966C-2B8B9689DBA4Q35041894-26DEB042-C708-460A-9C85-FE1DDA9E661FQ35042842-DECFD06F-D8A4-45B0-BFE6-C9D207C9364CQ35046135-331B120A-AD21-40EE-98D6-E75E2206052CQ35189866-C15BDD41-A8C9-4AD5-B9E5-AEDAC44B731CQ35541053-62AE2191-0EA7-4006-8B3E-D4C307DFD19EQ35602660-A363F299-6EDF-4A65-AB27-836A450C83DCQ35872756-A33E1E8A-27B3-42CC-B5CC-9E28AA9B6E28Q36181337-ED646E0E-0249-477C-9305-37A42DC3FC2DQ36330113-AFD53FCE-AE09-4C05-A160-A54EADF29C46Q36330430-76BDFA98-C437-4F7D-A7F0-EC6B0C0468A1Q36641577-D1E681BC-F372-4CC5-8651-A785FB0838C7Q36797320-845FC7C9-24D9-497B-A4D6-58B695DE3D33Q36817033-D2CDA84F-CDCD-4146-994D-0B23DD79A591Q36836794-6B4FD981-3241-470E-B940-1A1F157FB35EQ36868999-737539A9-C460-4F84-8686-08C7BA8D0650Q36869003-66CEA07B-5EC4-454A-AA38-F00440044FC7Q36873484-5CD185FF-EAD1-4D20-855B-CF1CD3A9C187Q36909258-ED355C6F-7A2E-4F0F-972A-9F9A467DAF67Q37293868-D2DF7AF3-60CE-438A-8D6B-01695D33EC17Q37409407-1AD0E445-BFC8-4FBF-8388-1881B46871A0Q37558323-17A2A95E-E7FD-4CF1-93F5-D99F252049EEQ37627183-2D11ECA6-21E0-495A-9A9A-F92DB08324E0
P2860
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
@ast
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
@en
type
label
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
@ast
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
@en
prefLabel
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
@ast
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
@en
P1476
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
@en
P2093
Moskowitz MA
P304
P356
10.1016/0165-6147(92)90097-P
P577
1992-08-01T00:00:00Z